HIV patients pause meds in antibody trial to see if virus stays suppressed
NCT ID NCT06908083
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study looks at whether a combination of two anti-HIV antibodies (bNAbs) can delay or lower the return of the virus after people stop their daily HIV medications. It involves 50 adults who previously received either the antibodies or a placebo in an earlier study. Participants will pause their HIV drugs and be closely monitored for up to 48 weeks to see how long the virus stays controlled and to understand the immune system's response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Rockefeller Institute
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.